A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients

Fidanci I. D., Zulfikar B., Kavakli K., Ar M. C., KILINÇ Y., Baslar Z., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.31, sa.1, ss.17-24, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4274/tjh.2012.0197
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.17-24
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: A severe complication in the replacement therapy of hemophilia A (HA) patients is the development of alloantibodies (inhibitors) against factor VIII, which neutralizes the substituted factor. The primary genetic risk factors influencing the development of inhibitors are F8 gene mutations. Interleukins and cytokines that are involved in the regulation of B-lymphocyte development are other possible targets as genetic risk factors. This study assesses the possible involvement of 9 selected single nucleotide gene polymorphisms (SNPs) with interleukins (IL-4, IL-5, and IL-10), transforming growth factor beta 1 (TGF-beta 1), and interferon gamma (IFN-gamma) in inhibitor development in severely affected HA patients carrying a null mutation in the F8 gene.